DNTH
VENTE TOTALE: 179 305 titres (~19 301 083,37 $ US)
- Insiders
- Read Simon, McGeorge Anne, Garcia Marino
- Total bought
- —
- Total sold
- $19,301,083
- Last activity
- 2026-08-19
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-06
DNTH presents a deeply unfavorable risk/reward profile: despite a Q2 earnings beat and early pipeline progress on DNTH312, the catalyst confidence is low (0.40) and heavily undermined by significant insider selling of…
The first sentence of the analysis written for DNTH on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | |
| Ebitda Margin | -7952.3% | -1356.2% | -1528.7% | -441.5% | -751.3% | |
| Operating Profit Margin | -8739.3% | -1633.7% | -1704.7% | -462.9% | -886.6% | |
| Pretax Profit Margin | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | |
| Continuous Operations Profit Margin | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | |
| Net Profit Margin | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | |
| Bottom Line Profit Margin | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | |
| Current Ratio | 13.323 | 15.223 | 18.425 | 9.974 | 16.634 | |
| Quick Ratio | 13.323 | 15.223 | 18.425 | 9.974 | 16.634 | |
| Solvency Ratio | -4.315 | -3.927 | -4.101 | -2.997 | -0.642 | |
| Cash Ratio | 1.662 | 1.235 | 13.739 | 1.868 | 12.119 | |
| Price To Earnings Ratio | -9.812 | -8.549 | -1.231 | -0.832 | -18.555 | |
| Price To Earnings Growth Ratio | -0.152 | 0.122 | -0.110 | -0.008 | 0.216 | |
| Forward Price To Earnings Growth Ratio | -0.152 | 0.122 | -0.110 | -0.008 | 0.216 | |
| Price To Earnings Diluted Ratio | -9.812 | -8.549 | -1.231 | -0.832 | -18.555 | |
| Price To Earnings Diluted Growth Ratio | -0.152 | 0.122 | -0.110 | -0.008 | 0.216 | |
| Price To Book Ratio | 3.157 | 2.060 | 0.317 | 0.322 | 1.410 | |
| Price To Sales Ratio | 764.978 | 116.479 | 18.965 | 3.691 | 164.921 | |
| Price To Free Cash Flow Ratio | -12.048 | -9.277 | -1.450 | -0.811 | -4.004 | |
| Price To Operating Cash Flow Ratio | -12.068 | -9.289 | -1.454 | -0.815 | -4.089 | |
| Debt To Assets Ratio | 0.003 | 0.004 | 0.003 | 0.009 | 0.000 | |
| Debt To Equity Ratio | 0.003 | 0.004 | 0.003 | 0.011 | 0.000 | |
| Debt To Capital Ratio | 0.003 | 0.004 | 0.003 | 0.011 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.002 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.076 | 1.061 | 1.062 | 1.128 | 1.100 | |
| Working Capital Turnover Ratio | 0.006 | 0.029 | 0.023 | 0.053 | 0.010 | |
| Operating Cash Flow Ratio | -4.200 | -4.237 | -3.827 | -3.534 | -5.480 | |
| Operating Cash Flow Sales Ratio | -63.389 | -12.539 | -13.044 | -4.530 | -40.333 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.001 | 1.003 | 1.005 | 1.021 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -93.117 | -52.435 | -63.010 | -36.891 | 0.000 | |
| Capital Expenditure Coverage Ratio | -605.915 | -744.571 | -335.100 | -209.137 | -47.097 | |
| Dividend Paid And Capex Coverage Ratio | -605.915 | -744.571 | -335.100 | -209.137 | -47.097 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.313 | -8.337 | 1.809 | -0.321 | -10.080 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 0.0% |
| Ebit Margin | -7973.3% | ▼-6610.6% | ▼-5531.5% |
| Ebitda Margin | -7952.3% | ▼-6596.1% | ▼-5546.3% |
| Operating Profit Margin | -8739.3% | ▼-7105.6% | ▼-6053.9% |
| Pretax Profit Margin | -7973.3% | ▼-6610.6% | ▼-5531.5% |
| Continuous Operations Profit Margin | -7973.3% | ▼-6610.6% | ▼-5531.5% |
| Net Profit Margin | -7973.3% | ▼-6610.6% | ▼-5531.5% |
| Bottom Line Profit Margin | -7973.3% | ▼-6610.6% | ▼-5531.5% |
| Current Ratio | 13.323 | ▼-1.901 | ▼-1.393 |
| Quick Ratio | 13.323 | ▼-1.901 | ▼-1.393 |
| Solvency Ratio | -4.315 | ▼-0.388 | ▼-1.119 |
| Cash Ratio | 1.662 | ▲0.427 | ▼-4.463 |
| Price To Earnings Ratio | -9.812 | ▼-1.263 | ▼-2.016 |
| Price To Earnings Growth Ratio | -0.152 | ▼-0.274 | ▼-0.165 |
| Forward Price To Earnings Growth Ratio | -0.152 | ▼-0.274 | ▼-0.165 |
| Price To Earnings Diluted Ratio | -9.812 | ▼-1.263 | ▼-2.016 |
| Price To Earnings Diluted Growth Ratio | -0.152 | ▼-0.274 | ▼-0.165 |
| Price To Book Ratio | 3.157 | ▲1.096 | ▲1.704 |
| Price To Sales Ratio | 764.978 | ▲648.499 | ▲551.171 |
| Price To Free Cash Flow Ratio | -12.048 | ▼-2.771 | ▼-6.530 |
| Price To Operating Cash Flow Ratio | -12.068 | ▼-2.779 | ▼-6.525 |
| Debt To Assets Ratio | 0.003 | ▼-0.001 | ▼-0.001 |
| Debt To Equity Ratio | 0.003 | ▼-0.001 | ▼-0.001 |
| Debt To Capital Ratio | 0.003 | ▼-0.001 | ▼-0.001 |
| Long Term Debt To Capital Ratio | 0.002 | ▲0.002 | ▲0.002 |
| Financial Leverage Ratio | 1.076 | ▲0.015 | ▼-0.009 |
| Working Capital Turnover Ratio | 0.006 | ▼-0.023 | ▼-0.018 |
| Operating Cash Flow Ratio | -4.199 | ▲0.037 | ▲0.056 |
| Operating Cash Flow Sales Ratio | -63.389 | ▼-50.850 | ▼-36.622 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▲0.000 | ▼-0.005 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -93.117 | ▼-40.682 | ▼-44.026 |
| Capital Expenditure Coverage Ratio | -605.915 | ▲138.656 | ▼-217.551 |
| Dividend Paid And Capex Coverage Ratio | -605.915 | ▲138.656 | ▼-217.551 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.313 | ▼-0.976 | ▼-4.064 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.56B | $726.2M | $53.6M | $23.7M | $243.4M | |
| Enterprise value | $1.51B | $704.9M | -$78.1M | $9.1M | $111.8M | |
| EV / Sales | 740.57x | 113.06x | -27.65x | 1.42x | 75.73x | |
| EV / Op. cash flow | -11.68x | -9.02x | 2.12x | -0.31x | -1.88x | |
| EV / Free cash flow | -11.66x | -9.01x | 2.11x | -0.31x | -1.84x | |
| EV / EBITDA | -9.31x | -8.34x | 1.81x | -0.32x | -10.08x | |
| Net debt / EBITDA | 0.31x | 0.25x | 3.05x | 0.52x | 11.87x | |
| Current ratio | 13.32x | 15.22x | 18.43x | 9.97x | 16.63x | |
| Income quality | 0.80x | 0.92x | 0.85x | 1.02x | 0.84x | |
| Graham net-net | $10 | $8 | $32 | $19 | $46 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $378.7M | $262.5M | $167.8M | $73.8M | $169.8M | |
| Invested capital | $380.3M | $264.2M | $168.6M | $74.8M | $177.3M | |
| Return on assets | -30.6% | -22.7% | -24.3% | -34.3% | -6.9% | |
| Operating ROA | -39.3% | -36.8% | -36.7% | -21.8% | -7.4% | |
| Return on tangible assets | -30.6% | -22.7% | -24.3% | -34.3% | -6.9% | |
| Return on equity | -32.9% | -24.1% | -25.8% | -38.7% | -7.6% | |
| Return on invested capital | -35.5% | -28.6% | -28.3% | -39.5% | -7.3% | |
| Return on capital employed | -35.6% | -28.6% | -28.4% | -39.7% | -7.3% | |
| Earnings yield | -10.4% | -11.7% | -81.3% | -120.2% | -5.4% | |
| Free cash flow yield | -8.3% | -10.8% | -69.0% | -123.3% | -25.0% | |
| Capex / Op. cash flow | -0.2% | -0.1% | -0.3% | -0.5% | -2.1% | |
| Capex / Depreciation | 49.8% | 25.5% | 31.0% | 94.6% | 62.6% | |
| Capex / Sales | 10.5% | 1.7% | 3.9% | 2.2% | 85.6% | |
| SG&A / Sales | 1686.2% | 400.9% | 642.6% | 105.1% | 132.5% | |
| R&D / Sales | 7153.1% | 1332.9% | 1162.1% | 457.8% | 854.1% | |
| Stock comp / Sales | 1119.5% | 206.8% | 102.6% | 23.7% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 18d | 47d | 62d | 321d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 18d | 47d | 62d | 321d | 0d | |
| Cash conversion cycle | 18d | 47d | 62d | 321d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+114.5%EV / Sales ▲+555.0%EV / EBITDA ▼-11.7%EV / Op. cash flow ▼-2.666Earnings yield ▲+0.013
Profitability
Return on equity ▼-0.088Return on assets ▼-0.079Return on invested capital ▼-0.069Return on capital employed ▼-0.069Operating ROA ▼-0.025Income quality ▼-0.125Tax burden 0.000
Efficiency
Days sales outstanding ▼-28.956Days payables outstanding n/aOperating cycle ▼-28.956Cash conversion cycle ▼-28.956Capex / Sales ▲+0.088R&D / Sales ▲+58.203
Balance-sheet strength
Current ratio ▼-1.901Net debt / EBITDA ▲+0.055Working capital ▲+116254000.000Invested capital ▲+116140000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+539.8%EV / Sales ▲+877.9%EV / EBITDA ▲+7.6%EV / Op. cash flow ▼-9.805Earnings yield ▼-0.050
Profitability
Return on equity ▼-0.253Return on assets ▼-0.237Return on invested capital ▼-0.282Return on capital employed ▼-0.283Operating ROA ▼-0.319Income quality ▼-0.042Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-0.752R&D / Sales ▲+62.991
Balance-sheet strength
Current ratio ▼-3.311Net debt / EBITDA ▼-11.565Working capital ▲+208876000.000Invested capital ▲+203048000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-10 Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.
- 2026-08-09 California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,584 shares of the company''s stock after buying an additional
- 2026-08-06 Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 325,440 shares of the company''s stock after purchasing an additional 114,767 shares during the quarter. Dimensional Fund Advisors
- 2026-08-04 Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
- 2026-08-04 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H''28 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE''26 Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December ''26 Building a rheumatology franchise with DNTH212 across our first three prioritized indications of Sjögren''s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM); Phase 1 healthy volunteer data anticipated by YE''26 Advancing DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases; DNTH312 aims to be Phase 1 ready by YE''27 Approximately $1.2 billion of cash as of June 30, 2026 provides expected runway into 2030 NEW YORK and WALTHAM, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2026, and provided an update on other recent business achievements.
- 2026-08-04 Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs By building on claseprubart''s best-in-class profile, DNTH312 strengthens Dianthus'' leadership in neuromuscular disease, while expanding into additional autoimmune diseases where both B cell modulation and Classical Pathway inhibition could provide additional benefits to more patients DNTH312 aims to be Phase 1 ready by YE''27 NEW YORK and WALTHAM, Mass.
- 2026-08-03 Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees.
- 2026-07-02 Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.
- 2026-06-29 Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H''28
- 2026-06-17 DNTH Shares Surge 89% Over the Past Six Months: What''s Driving It? Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.